Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CG Oncology, Inc. ( (CGON) ) has shared an announcement.
On September 5, 2025, CG Oncology announced updated data from its Phase 3 BOND-003 Cohort C trial, showing a 24-month complete response rate of 41.8% for cretostimogene monotherapy in high-risk non-muscle invasive bladder cancer patients unresponsive to BCG treatment. The trial demonstrated strong durability and tolerability, with no severe treatment-related adverse events reported, and 96.6% of patients were free from progression to muscle invasive disease at 24 months. The company plans to submit a Biologics License Application for cretostimogene in the fourth quarter of 2025, positioning it as a potential breakthrough treatment in this patient population.
The most recent analyst rating on (CGON) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.
Spark’s Take on CGON Stock
According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.
CG Oncology, Inc. has a moderate stock score driven by positive technical indicators and a stable financial foundation despite ongoing financial challenges. The lack of revenue and reliance on external funding are significant risks, but the stock’s current bullish momentum provides some optimism.
To see Spark’s full report on CGON stock, click here.
More about CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative bladder-sparing therapeutics for bladder cancer patients. The company aims to enhance the quality of life for urologic cancer patients through its immunotherapies.
Average Trading Volume: 818,055
Technical Sentiment Signal: Buy
Current Market Cap: $2.36B
See more data about CGON stock on TipRanks’ Stock Analysis page.